Is a new revolution in lung cancer drug treatment coming ?

22/09/2014 - 3 minutes

A new revolutionary treatment could help cure lung cancer. It is based on mRNA instead of antibodies and chemotherapy. Instead of delivering the protein or the drug, only a message is delivering and the body will produce the therapeutics. Curevac, the historic and one of the leading Biotech company in this field announced a 465 million euros deal with top 20 german pharma company Boehringer Ingelheim

The deal concerns the german cancer vaccine CV9202, developed by Curevac and now licensed entirely to Boehringer Ingelheim. This treatment will be paired with it’s own Gilotrif chemotherapy drugs. The goal is to obtain a superior efficacy and treat severe and inoperable phase 3 cancers. Gilotrif has been authorized recently and shows moderated efficacy. Patients taking the drug had 11.1 months of progression-free survival instead of 6.9 months with traditional therapies. The pharma company believes it can do better by using Curevac’s exclusive technology.

CureVac_Picture therapy

The technology is based on mRNA encoding specific cancer antigens – proteins enabling cancer cell recongnition.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member